Table 4. Treatment-Emergent Adverse Events.
Insulin (n = 15) | Insulin + tofogliflozin (n = 19) | Glargine + tofogliflozin (n = 19) | |
---|---|---|---|
Hypoglycemia (n) | 4 | 5 | 4 |
*Patient self-reporting only. Number of patients with hypoglycemia during the follow-up period. There were no significant differences among the groups.